Fig. 2

The impact of TNFα treatment on endothelial inflammatory/injury markers. CB-ECFCs were treated with different TNFα doses for 24 h and assessed for the percentage of expression and the mean fluorescent intensity of their surface markers. a The expression of ICAM among total CD31⁺CD144⁺ cells (n = 8), b the expression of VCAM among CD31⁺CD144⁺ cells (n = 8), c the expression of TIE-2 among CD31⁺CD144⁺ cells (n = 8), d the percentage of annexin⁺PI⁻ apoptotic cells among CD31⁺CD144⁺ cells (n = 8). In representative flow cytometry panels, red histograms depict the expression of desired marker on untreated ECFCs. The other colourful histograms depict the expression of desired marker on ECFCs after treating with the following doses of TNFα: blue: 0.01 ng/ml; orange: 0.1 ng/ml; light green: 1 ng/ml; dark green: 10 ng/ml; pink: 50 ng/ml; purple: 100 ng/ml. Representative flow cytometry dot plots show the percentage of apoptotic ECFCs after 1 ng/ml of TNFα treating. Data are represented as mean value ± SEM from 2 independent experiments. One way ANOVA or Student t test analysis was performed to generate P values. ns: non-significant, *P < .05; **P < .01; ***P < .001